Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. González-García R, Naval-Gías L, Martos PL. Melanoma of the oral mucosa. Clinical cases and review of the literature. Med Oral Patol Oral Cir Bucal 2005; 10: 264–271.
-
2. Tanaka N, Mimura M, Ogi K, et al. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients. Int J Oral Maxillofac Surg 2004; 33: 761–765.
-
3. Liptak JM, Withrow SJ. Cancer of the gastrointestinal tract. In: Small animal clinical oncology. St Louis: Saunders, 2007; 455–475.
-
4. Liptak JM, Lascelles BX. Oral tumors. In: Kudnig ST, Séguin B, eds. Veterinary surgical oncology. Ames, Iowa: Wiley Blackwell, 2012;119–178.
-
5. Murphy S, Hayes AM, Blackwood L, et al. Oral malignant melanoma—the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol 2005; 3: 222–229.
-
6. Blackwood L, Dobson JM. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 1996; 209: 98–102.
-
7. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 2003; 44: 352–359.
-
8. Brockley LK, Cooper MA, Bennett PF. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. N Z Vet J 2013; 61: 25–31.
-
9. Dank G, Rassnick KM, Sokolovsky Y, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. Vet Comp Oncol 2014; 12: 78–84.
-
10. Taylor KH, Smith AN, Higginbotham M, et al. Expression of vascular endothelial growth factor in canine oral malignant melanoma. Vet Comp Oncol 2007; 5: 208–218.
-
11. USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 2010; 236: 495.
-
12. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284–1290.
-
13. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011; 72: 1631–1638.
-
14. Ottnod JM, Smedley RC, Walshaw R, et al. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 2013; 11: 219–229.
-
15. Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Vet Pathol 2011; 48: 54–72.
-
16. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987–2001). J Am Vet Med Assoc 2003; 222: 1234–1236.
-
17. Suton P, Lukšić I, Müller D, et al. Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes? Int J Oral Maxillofac Surg 2012; 41: 413–420.
-
18. Sun CZ, Chen YF, Jiang YE, et al. Treatment and prognosis of oral mucosal melanoma. Oral Oncol 2012; 48: 647–652.
-
19. Bodem JP, Gülicher D, Engel M, et al. Role of neck dissection in the treatment of melanoma of the head and neck. J Craniofac Surg 2013; 24: 483–487.
-
20. Hahn KA, DeNicola DB, Richardson RC, et al. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 1994; 35: 251–256.
-
21. Bast RC, Kufe DW, Pollock RE, et al. Principles of surgical oncology. In: Holland JC, Frei E, eds. Cancer medicine. 5th ed. Hamilton, ON, Canada: BC Decker, 2000.
Advertisement
Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012)
Abstract
Objective—To determine prognostic factors for and compare outcome among dogs with oral malignant melanoma following excision with or without various systemic adjuvant therapies.
Design—Retrospective case series.
Animals—151 dogs with naturally occurring oral malignant melanomas treated by excision with or without adjuvant therapies from 2001 to 2012.
Procedures—Case accrual was solicited from Veterinary Society of Surgical Oncology members via an email list service. Information collected from case records included signalment, tumor staging, tumor characteristics, type of surgical excision, histologic diagnosis, adjuvant therapy, and survival time.
Results—The overall median survival time was 346 days. Results of multivariate analysis indicated that tumor size, patient age, and intralesional excision (vs marginal, wide, or radical excision) were considered poor prognostic indicators. All other demographic and clinical variables were not significantly associated with survival time after adjusting for the aforementioned 3 variables. A clear survival benefit was not evident with any systemic adjuvant therapy, including vaccination against melanoma or chemotherapy; however, the number of dogs in each treatment group was small. Ninety-eight dogs received no postoperative adjuvant therapy, and there was no difference in survival time between dogs that did (335 days) and did not (352 days) receive systemic adjuvant therapy.
Conclusions and Clinical Relevance—For dogs with oral malignant melanoma, increasing tumor size and age were negative prognostic factors. Complete excision of all macroscopic tumor burden improved survival time. Long-term survival was possible following surgery alone. Although systemic adjuvant therapy was not found to improve survival time, this could have been due to type II error.
Contributor Notes
Supported by the Veterinary Society of Surgical Oncology Research Committee.
Powered by PubFactory